Insulin aspart-fsan (Garzulys)
Dilution requiredFull monograph review pending
U.S. label preparation
Garzulys · Dilution required
- Preparation
- For supervised IV use, dilute U-100 insulin aspart from the vial to 0.05 to 1 unit/mL in a polypropylene infusion bag. The label lists 0.9% sodium chloride as a compatible infusion fluid.
- Administration and handling
- Monitor blood glucose and potassium closely. The pen, subcutaneous dilution instructions and pump instructions do not apply to this preparation.
Product and source details
Meitheal Pharmaceuticals Inc. · BLA761497
Product NDC: 71288-904
SPL effective 2026-07-31 | SPL version 9. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.